Recently, Ausper Biopharma Co., Ltd. (“Ausper”) announced the successful completion of its share repurchase program, having acquired a total of 3,000,000 shares—representing 0.75% of its total share capital—at an aggregate cost of approximately RMB 60.03 million. The repurchase reflects the company’s confidence in its future growth prospects and its recognition of its intrinsic value, aiming to protect shareholder interests, bolster market confidence, and optimize its capital structure.According to the announcement, the repurchased shares will be used for an employee stock ownership plan or equity-based incentives, aligning the long-term interests of key personnel with those of the company and enhancing organizational cohesion and competitiveness. Ausper stated that the repurchase was funded entirely from its own resources and will not materially affect its normal operations or financial health. As a pharmaceutical company specializing in the research, development, manufacturing, and sales of high-end specialty active pharmaceutical ingredients (APIs) and finished dosage forms, Ausper has consistently increased R&D investment and expanded its presence in both domestic and international markets, demonstrating steady growth. This share buyback further signals strong confidence from management in the company’s future trajectory.
近日，奥锐特药业股份有限公司（简称“奥锐特”）发布公告称，公司已顺利完成股份回购计划，累计回购股份数量为3,000,000股，占公司总股本的0.75%，回购总金额约为6003万元人民币。此次回购是基于对公司未来发展前景的信心以及对自身价值的认可，旨在维护广大投资者利益、增强市场信心，并进一步优化公司资本结构。根据公告，本次回购的股份将用于实施员工持股计划或股权激励，有助于绑定核心团队与公司长期利益，提升企业凝聚力和竞争力。奥锐特表示，回购资金来源于公司自有资金，不会对公司正常经营及财务状况造成重大影响。作为一家专注于高端特色原料药及制剂研发、生产与销售的医药企业，奥锐特近年来持续加大研发投入，积极拓展国内外市场，展现出稳健的发展态势。此次股份回购也向市场传递了公司管理层对未来发展的坚定信心。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/19096.html